A Novel Homozygous Missense Variant in the NAGA Gene with Extreme Intrafamilial Phenotypic Heterogeneity

  • Fedah E. Mohamed
  • Mohammad Al Sorkhy
  • Mohammad A. Ghattas
  • Nuha Al-Zaabi
  • Aisha Al-Shamsi
  • Taleb M. Almansoori
  • Lihadh Al-Gazali
  • Osama Y. Al-Dirbashi
  • Fatma Al-JasmiEmail author
  • Bassam R. AliEmail author


Schindler disease is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in alpha-N-acetylgalactosaminidase (α-NAGA) activity due to defects in the NAGA gene. Accumulation of the enzyme’s substrates results in clinically heterogeneous symptoms ranging from asymptomatic individuals to individuals with severe neurological manifestations. Here, a 5-year-old Emirati male born to consanguineous parents presented with congenital microcephaly and severe neurological manifestations. Whole genome sequencing revealed a homozygous missense variant (c.838C>A; p.L280I) in the NAGA gene. The allele is a reported SNP in the ExAC database with a 0.0007497 allele frequency. The proband’s asymptomatic sister and cousin carry the same genotype in a homozygous state as revealed from the family screening. Due to the extreme intrafamilial heterogeneity of the disease as seen in previously reported cases, we performed further analyses to establish the pathogenicity of this variant. Both the proband and his sister showed abnormal urine oligosaccharide patterns, which is consistent with the diagnosis of Schindler disease. The α-NAGA activity was significantly reduced in the proband and his sister with 5.9% and 12.1% of the mean normal activity, respectively. Despite the activity loss, p.L280I α-NAGA processing and trafficking were not affected. However, protein molecular dynamic simulation analysis revealed that this amino acid substitution is likely to affect the enzyme’s natural dynamics and hinders its ability to bind to the active site. Functional analysis confirmed the pathogenicity of the identified missense variant and the diagnosis of Schindler disease. Extreme intrafamilial clinical heterogeneity of the disease necessitates further studies for proper genetic counseling and management.


Schindler disease NAGA gene Alpha-N-acetylgalactosaminidase Enzymatic activity Whole genome sequencing Congenital microcephaly 



We are indebted to the family for their participation in this study.

Authors Contributions

FJ performed the clinical evaluation, planned the biochemical and molecular testing/screening, and interpreted the findings. FEM and BA designed the experimental plan. FEM performed the biochemical and molecular analyses, in silico prediction, and analyzed the data. MAS and MAG performed molecular modeling analysis. OAD reviewed the activity assay analysis. NAZ and AAS performed the clinical evaluation. TAM reported the brain MRI findings. FEM wrote the manuscript. All authors read and approved the final manuscript.

Funding Information

This study was supported by research grants from the United Arab Emirates University (grants 31R018 and 31R134).

Compliance with Ethical Standards

Ethics Approval and Consent to Participate

All procedures performed in studies involving human participants were in accordance with Al-Ain Medical Human Research Ethics Committee (AMHREC) according to the national regulations (approval numbers 10/09 and ERH-2015-3241 15–115) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Samples and images were collected from the proband and his sister after obtaining written informed consents from the parents.

Informed Consent

Informed consent was obtained from all individual participants included in the study. Additional informed consents were obtained from all individual participants for whom identifying information is included in this article.

Competing Interests

The authors declare that they have no competing interests.


  1. Adzhubei IA et al (2010) A method and server for predicting damaging missense mutations. In: Nat Methods, vol 7. vol 4. United States, pp 248–249. doi:10.1038/nmeth0410-248Google Scholar
  2. Al-Jasmi FA et al (2013) Prevalence and novel mutations of lysosomal storage disorders in United Arab Emirates: LSD in UAE. JIMD reports 10:1–9. CrossRefPubMedPubMedCentralGoogle Scholar
  3. Alroy J, Lyons JA (2014) Lysosomal storage diseases: doi:10.1177_2326409813517663Google Scholar
  4. Bakker HD, de Sonnaville ML, Vreken P, Abeling NG, Groener JE, Keulemans JL, van Diggelen OP (2001) Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy? European journal of human genetics : EJHG 9:91–96. CrossRefPubMedGoogle Scholar
  5. Bateman A et al (2018) UniProt: the universal protein knowledgebase. Nucleic Acids Res 45:D158–D169. CrossRefGoogle Scholar
  6. Berman HM et al (2018) The Protein Data Bank Nucleic Acids Research 28:235–242. CrossRefGoogle Scholar
  7. Chabas A, Duque J, Gort L (2007) A new infantile case of alpha-N-acetylgalactosaminidase deficiency. Cardiomyopathy as a presenting symptom. J Inherit Metab Dis 30:108. CrossRefPubMedGoogle Scholar
  8. Clark NE, Garman SC (2009) The 1.9 Å structure of human α-N-acetylgalactosaminidase: the molecular basis of Schindler and Kanzaki diseases. J Mol Biol 393:435–447. CrossRefPubMedPubMedCentralGoogle Scholar
  9. Cutting GR (2010) Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci 1214:57–69. CrossRefPubMedPubMedCentralGoogle Scholar
  10. Davidson BA, Hassan S, Garcia EJ, Tayebi N, Sidransky E (2018) Exploring genetic modifiers of Gaucher disease: the next horizon. Hum Mutat 39:1739–1751. CrossRefPubMedGoogle Scholar
  11. ExPASy - Translate tool. (2019). Accessed 15 March 2018
  12. Filippi PD et al (2014) Genotype-phenotype correlation in Pompe disease, a step forward. Orphanet Journal of Rare Diseases 9:102. CrossRefPubMedPubMedCentralGoogle Scholar
  13. Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 337:319–335. CrossRefPubMedGoogle Scholar
  14. Gonzalez EA, Baldo G (2017) Gene therapy for lysosomal storage disorders: recent advances and limitations JIEMS doi:10.1177_2326409816689786Google Scholar
  15. Hu P, Reuser AJJ, Janse HC, Kleijer WJ, Schindler D, Sakuraba H, Tsuji A, Suzuki Y, van Diggelen OP (1991) Biosynthesis of human alpha-N-acetylgalactosaminidase: defective phosphorylation and maturation in infantile alpha-NAGA deficiency. Biochem Biophys Res Commun 175:1097–1103CrossRefPubMedGoogle Scholar
  16. Irahara-Miyana K, Otomo T, Kondo H, Hossain MA, Ozono K, Sakai N (2018) Unfolded protein response is activated in Krabbe disease in a manner dependent on the mutation type. J Hum Genet 63:699–706. CrossRefPubMedGoogle Scholar
  17. Keulemans JL, Reuser AJ, Kroos MA, Willemsen R, Hermans MM, van den Ouweland AM, de Jong JG, Wevers RA, Renier WO, Schindler D, Coll MJ, Chabas A, Sakuraba H, Suzuki Y, van Diggelen OP (1996) Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: new mutations and the paradox between genotype and phenotype. J Med Genet 33:458–464CrossRefPubMedPubMedCentralGoogle Scholar
  18. Kodama K, Kobayashi H, Abe R, Ohkawara A, Yoshii N, Yotsumoto S, Fukushige T, Nagatsuka Y, Hirabayashi Y, Kanzaki T (2001) A new case of alpha-N-acetylgalactosaminidase deficiency with angiokeratoma corporis diffusum, with Meniere's syndrome and without mental retardation. Br J Dermatol 144:363–368CrossRefPubMedGoogle Scholar
  19. Kousi M, Katsanis N (2015) Genetic modifiers and oligogenic inheritance. Cold Spring Harbor perspectives in medicine 5.
  20. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081. CrossRefPubMedGoogle Scholar
  21. Lek M et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285–291. CrossRefPubMedPubMedCentralGoogle Scholar
  22. Meshach Paul D, Rajasekaran R (2018) Exploration of structural and functional variations owing to point mutations in alpha-NAGA. Interdisciplinary sciences, computational life sciences 10:81–92. CrossRefPubMedGoogle Scholar
  23. Mohamed FE, Al-Gazali L, Al-Jasmi F, Ali BR (2017) Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises. Front Pharmacol 8:448. CrossRefPubMedPubMedCentralGoogle Scholar
  24. PMC E (2015) The EMBL-EBI bioinformatics web and programmatic tools framework. - Abstract - Europe PMC. Accessed April 2017
  25. Ron I, Horowitz M (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 14:2387–2398. CrossRefPubMedGoogle Scholar
  26. Schneider TD, Stephens RM (1990) Sequence logos: a new way to display consensus sequences. Nucleic Acids Res 18:6097–6100CrossRefPubMedPubMedCentralGoogle Scholar
  27. Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 11:361–362. CrossRefPubMedGoogle Scholar
  28. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NST, Abeysinghe S, Krawczak M, Cooper DN (2003) Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21:577–581. CrossRefPubMedGoogle Scholar
  29. Valenzano KJ, Khanna R, Powe AC, Boyd R, Lee G, Flanagan JJ, Benjamin ER (2011) Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. In: Assay Drug Dev Technol, vol 9. vol 3. pp 213–235. doi:
  30. Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJG, Wevers RA, van Diggelen OP, Poorthuis BJ, Halley DJ, Wijburg FA (2010) Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 68:876–887. CrossRefPubMedGoogle Scholar
  31. van Diggelen OP et al (1988) alpha-N-acetylgalactosaminidase deficiency, a new lysosomal storage disorder. Journal of inherited metabolic disease 11:349–357CrossRefPubMedGoogle Scholar
  32. Wang AM, Kanzaki T, Desnick RJ (1994) The molecular lesion in the alpha-N-acetylgalactosaminidase gene that causes angiokeratoma corporis diffusum with glycopeptiduria. J Clin Invest 94:839–845. CrossRefPubMedPubMedCentralGoogle Scholar
  33. Wang AM, Schindler D, Desnick R (1990) Schindler disease: the molecular lesion in the alpha-N-acetylgalactosaminidase gene that causes an infantile neuroaxonal dystrophy. J Clin Invest 86:1752–1756. CrossRefPubMedPubMedCentralGoogle Scholar
  34. Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, Billis K, Cummins C, Gall A, Girón CG, Gil L, Gordon L, Haggerty L, Haskell E, Hourlier T, Izuogu OG, Janacek SH, Juettemann T, To JK, Laird MR, Lavidas I, Liu Z, Loveland JE, Maurel T, McLaren W, Moore B, Mudge J, Murphy DN, Newman V, Nuhn M, Ogeh D, Ong CK, Parker A, Patricio M, Riat HS, Schuilenburg H, Sheppard D, Sparrow H, Taylor K, Thormann A, Vullo A, Walts B, Zadissa A, Frankish A, Hunt SE, Kostadima M, Langridge N, Martin FJ, Muffato M, Perry E, Ruffier M, Staines DM, Trevanion SJ, Aken BL, Cunningham F, Yates A, Flicek P (2018) Ensembl 2018. Nucleic Acids Res 46:D754–D761. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pathology, College of Medicine and Health SciencesUnited Arab Emirates UniversityAl AinUnited Arab Emirates
  2. 2.College of PharmacyAl Ain University of Science and TechnologyAl AinUnited Arab Emirates
  3. 3.Department of Paediatrics, College of Medicine and Health SciencesUnited Arab Emirates UniversityAl AinUnited Arab Emirates
  4. 4.Department of PaediatricsTawam HospitalAl AinUnited Arab Emirates
  5. 5.Department of Radiology, College of Medicine and Health SciencesUnited Arab Emirates UniversityAl AinUnited Arab Emirates

Personalised recommendations